2025-10-20 - Analysis Report
Okay, here's a report analyzing TG Therapeutics (TGTX), incorporating the data you provided.

**Report: TG Therapeutics (TGTX) Analysis**

**0. Introduction**

This report analyzes TG Therapeutics Inc. (TGTX), a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.  The analysis includes a review of stock performance, technical indicators, recent news, analyst opinions, earnings data, and financial information.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TGTX
*   **Company:** TG Therapeutics Inc
*   **TGTX Cumulative Return:** 83.02%
*   **VOO Cumulative Return:** 97.05%
*   **Absolute Deviation:** -14.0
*   **Relative Deviation:** 21.4 (Indicates that the deviation is in the 21.4th percentile of its historical range relative to the S&P 500.)

**Analysis of Historical Performance (Alpha, Beta, CAGR, MDD):**

| Year       | CAGR   | MDD   | Alpha   | Beta  | Cap (B) |
|------------|--------|--------|---------|-------|---------|
| 2015-2017  | -5.0%  | 73.5%  | -33.0%  | -0.0  | 1.3     |
| 2016-2018  | -12.0% | 73.5%  | -27.0%  | -0.0  | 0.7     |
| 2017-2019  | 74.0%  | 74.1%  | 52.0%   | 0.0   | 1.8     |
| 2018-2020  | 316.0% | 74.1%  | 293.0%  | 0.1   | 8.2     |
| 2019-2021  | 124.0% | 74.1%  | 78.0%   | 0.3   | 3.0     |
| 2020-2022  | -71.0% | 77.8%  | -71.0%  | -0.0  | 1.9     |
| 2021-2023  | -284.0%| 77.8%  | -285.0% | -1.1  | 2.7     |
| 2022-2024  | 56.0%  | 77.8%  | 36.0%   | -1.0  | 4.8     |
| 2023-2025  | 83.0%  | 80.7%  | 22.0%   | -0.1  | 5.5     |

*   **Analysis:** The historical data reveals periods of significant outperformance (e.g., 2018-2020) and underperformance (e.g., 2021-2023) relative to the market. The beta values are generally low, sometimes negative, suggesting a weak correlation with the S&P 500. The wide fluctuations in CAGR and Alpha indicate a high degree of volatility and potential for both substantial gains and losses.

**2. Recent Stock Price Movement**

*   **Current Price:** 34.67
*   **Previous Close:** 34.87
*   **Change:** -0.57
*   **5-Day Moving Average:** 34.59
*   **20-Day Moving Average:** 35.4162
*   **60-Day Moving Average:** 32.2435

*   **Analysis:** The current price is slightly below the 5-day moving average and significantly below the 20-day moving average, suggesting potential short-term downward pressure. However, it's above the 60-day moving average, indicating a longer-term upward trend. The recent price decrease is relatively small.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment - indicates moderate risk)
*   **RSI:** 34.87 (Approaching oversold territory - typically below 30)
*   **PPO:** -0.85 (Negative, indicating the shorter-term moving average is below the longer-term moving average.)
*   **Hybrid Signal:** Cash_80%_Sell (80% of holdings suggested)
*   **Delta_Previous_Relative_Divergence:** 0.4 (+), indicating short-term upward momentum
*   **Expected Return:** -105.3% (Relatively low compared to S&P 500 over a 2+ year investment horizon)

*   **Analysis:** The MRI suggests a low investment recommendation, and the RSI is nearing oversold territory. The PPO confirms the downward trend, while the hybrid signal suggests a cautious approach with a significant cash position. The negative expected return indicates that, based on this model, TGTX is expected to underperform the S&P 500 over the long term. The recent increase in relative divergence could suggest a short-term bounce is possible. The slight price decrease should not be the main point to consider, there may be more important facts.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   Institutional investors are major shareholders and benefited from recent market cap gains.
    *   6-year safety data for BRIUMVI (TGTX's multiple sclerosis treatment) are positive.
    *   Data shows a high percentage of MS patients are free from disability progression after 6 years of BRIUMVI treatment.
    *   Neuraxpharm's commitment to multiple sclerosis is highlighted, though the direct link to TGTX is unclear.

*   **Analysis:** The news is primarily positive, highlighting the success of BRIUMVI and institutional investor confidence. The focus on long-term safety and efficacy data for BRIUMVI is particularly important.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.78 (Buy)
*   **Number of Opinions:** 7
*   **Target Price:**
    *   Average: 43.57
    *   High: 60.00
    *   Low: 11.00
*   **Analysis:** Analyst consensus is generally positive, with a "Buy" rating and a significantly higher average target price than the current price.  The large range in target prices suggests uncertainty among analysts. Recent Rating Changes are not provided.

**5. Recent Earnings Analysis**

| 날짜         | EPS  | 매출       |
|--------------|------|------------|
| 2025-08-08  | 0.19 | 0.14 B$  |
| 2025-05-09  | 0.03 | 0.12 B$  |
| 2024-11-07  | 0.03 | 0.08 B$  |
| 2024-08-09  | 0.05 | 0.07 B$  |
| 2025-08-08  | 0.05 | 0.07 B$  |

*   **Analysis:** The most recent EPS was $0.19, a significant increase from previous quarters. Revenue has generally been increasing. The positive earnings trend supports a bullish outlook.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30  | $0.14B   | 86.58%        |
| 2025-03-31  | $0.12B   | 87.14%        |
| 2024-12-31  | $0.11B   | 85.77%        |
| 2024-09-30  | $0.08B   | 88.86%        |
| 2024-06-30  | $0.07B   | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-06-30  | $0.28B   | 10.20% |
| 2025-03-31  | $0.24B   | 2.13%  |
| 2024-12-31  | $0.22B   | 10.49% |
| 2024-09-30  | $0.19B   | 2.02%  |
| 2024-06-30  | $0.18B   | 3.87%  |

*   **Analysis:** Revenue and profit margins are strong. Equity is increasing, and ROE has fluctuated but is currently at a decent level. The data indicate positive financial health.

**7. Overall Summary and Conclusion**

TGTX presents a mixed picture.

*   **Positives:**
    *   Positive analyst consensus with a "Buy" rating and significant upside potential in target prices.
    *   Strong revenue growth and high profit margins.
    *   Positive news flow regarding BRIUMVI's efficacy and safety.
    *   Increasing equity and recent earnings improvement.

*   **Negatives:**
    *   Underperformance relative to the S&P 500.
    *   Negative expected return based on the model.
    *   High volatility, as indicated by historical data.
    *   Hybrid Signal suggest a cautious approach with a significant cash position.

**Conclusion:** While TGTX has positive aspects, including strong financials and analyst ratings, the underperformance relative to the market and the negative expected return raise concerns. Investors should weigh the potential upside from BRIUMVI's success against the risks associated with the company's volatility and recent underperformance. A cautious approach, as suggested by the hybrid signal, may be warranted.
